Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768413 | 1.00 | PDE4B (0.48) | PDE4BRORCTACR1MC4RESR2 | |
| SCHEMBL23216432 | 1.00 | PDE4B (0.48) | PDE4BRORCTACR1MC4RESR2 | |
| SCHEMBL29768419 | 0.89 | PDE4B (0.49) | PDE4BRORCTACR1MC4RESR2 | |
| SCHEMBL23216936 | 0.89 | PDE4B (0.49) | PDE4BRORCTACR1MC4RESR2 | |
| SCHEMBL24946333 | 0.89 | PDE4B (0.49) | PDE4BRORCTACR1MC4RESR2 | |
| SCHEMBL29885822 | 0.88 | PDE4B (0.57) | PDE4BRORCTACR1USP30 | |
| SCHEMBL23239759 | 0.88 | PDE4B (0.57) | PDE4BRORCTACR1USP30 | |
| SCHEMBL23216555 | 0.88 | PDE4B (0.57) | PDE4BRORCTACR1USP30 | |
| SCHEMBL6310349 | 0.85 | DPP4 (0.53) | PDE4BRORCTACR1MC4RCNR1 | |
| SCHEMBL16780714 | 0.82 | PDE4B (0.48) | PDE4BRORCTACR1CNR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNA3, KCNH2, KCNJ2 | PDE4B 997/4885RORC 2290/4885TACR1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.